The Association Between Oxygenation Thresholds and Mortality During Extracorporeal Life Support

Similar documents
Oxygen:..Nothing is without poison.. the poison is in the dose..

Outcomes From Severe ARDS Managed Without ECMO. Roy Brower, MD Johns Hopkins University Critical Care Canada Forum Toronto November 1, 2016

The Utility of Extravascular Lung Water Measurements Following Bilateral Lung Transplant

Adult Extracorporeal Life Support (ECLS)

10/16/2017. Review the indications for ECMO in patients with. Respiratory failure Cardiac failure Cardiorespiratory failure

Extracorporeal Membrane Oxygenation (ECMO)

ECLS as Bridge to Transplant

Extracorporeal Membrane Oxygenation (ECMO)

ECLS Registry Form Extracorporeal Life Support Organization (ELSO)

Ventilator ECMO Interactions

Veno-Venous ECMO Support. Chris Cropsey, MD Sept. 21, 2015

Management of Respiratory Failure: The Surgical Perspective. When Traditional Respiratory Support Techniques fail. ARDS: Evidence Based Practice

Management of Severe ARDS: Current Canadian Practice

Post Arrest Ventilation/Oxygenation Management

Extracorporeal Life Support (ECLS) as a Bridge to Decision in Lung Transplantation

ECMO FOR PEDIATRIC RESPIRATORY FAILURE. Novik Budiwardhana * PCICU Harapan Kita National Cardiovascular Center Jakarta

Facilitating EndotracheaL Intubation by Laryngoscopy technique and Apneic Oxygenation Within the Intensive Care Unit (FELLOW)

Exclusion Criteria 1. Operator or supervisor feels specific intra- procedural laryngoscopy device will be required.

ECLS Bridge to Lung Transplantation Optimizing and Ambulating the Recipient

ECMO for Severe Hypoxemic Respiratory Failure: Pro-Con Debate. Carolyn Calfee, MD MAS Mark Eisner, MD MPH

NIV in Acute Respiratory Failure: Where we fail? Dr Shrikanth Srinivasan MD,DNB,FNB,EDIC Consultant, Critical Care Medicine Medanta, The Medicity

9/5/2018. Conflicts of Interests. Pediatric Acute Respiratory Distress Syndrome. Objectives ARDS ARDS. Definitions. None

Extracorporeal support in acute respiratory failure. Dr Anthony Bastin Consultant in critical care Royal Brompton Hospital, London

Case scenario V AV ECMO. Dr Pranay Oza

ECMO: a breakthrough in care for respiratory failure. PD Dr. Thomas Müller Regensburg no conflict of interest

Pro: Early use of VV ECMO for ARDS

Outcomes Using Extracorporeal Life Support for Adult Respiratory Failure due to Status Asthmaticus

Part 2 of park s Ventilator and ARDS slides for syllabus

ECMO vs. CPB for Intraoperative Support: How do you Choose?

In the setting of liver failure & transplantation?

Extracorporeal Life Support (ECLS)

CASE PRESENTATION VV ECMO

Lesta Whalen, MD Medical Director, Sanford ECMO Pediatric Critical Care

Arterial Blood Gas Analysis

ARDS and Ventilators PG26 Update in Surgical Critical Care October 9, 2013

Management of Post Cardiac Arrest Syndrome

ARDS: an update 6 th March A. Hakeem Al Hashim, MD, FRCP SQUH

PEEP recruitment maneuver

Extracorporeal Life Support Organization (ELSO) Guidelines for Pediatric Respiratory Failure

ARDS and Lung Protection

A simple case of.. Acute severe asthma. MasterclassIC Schiermonnikoog 2017

ECMO and refractory Hypoxemia

Extracorporeal Membrane Oxygenation (ECMO) Referrals

Section: Therapy Effective Date: October 15, 2016 Subsection: Original Policy Date: June 19, 2015 Subject:

ECMO BASICS CHLOE STEINSHOUER, MD PULMONARY AND SLEEP CONSULTANTS OF KANSAS

OSCAR & OSCILLATE. & the Future of High Frequency Oscillatory Ventilation (HFOV)

Wanchai Wongkornrat Cardiovascular Thoracic Surgery Siriraj Hospital Mahidol University

The use of proning in the management of Acute Respiratory Distress Syndrome

Extracorporeal Life Support Organization (ELSO)

Management of refractory ARDS. Saurabh maji

APPENDIX VI HFOV Quick Guide

ARDS Assisted ventilation and prone position. ICU Fellowship Training Radboudumc

ACUTE RESPIRATORY DISTRESS SYNDROME

Landmark articles on ventilation

5. What is the cause of this patient s metabolic acidosis? LACTIC ACIDOSIS SECONDARY TO ANEMIC HYPOXIA (HIGH CO LEVEL)

AllinaHealthSystem 1

ARDS and treatment strategies

ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) Rv

Samphant Ponvilawan Bumrungrad International

Arterial Blood Gases Interpretation Definition Values respiratory metabolic

Research in ECMO: A revolution is coming

Fluid Resuscitation in Critically Ill Patients with Acute Kidney Injury (AKI)

7/4/2015. diffuse lung injury resulting in noncardiogenic pulmonary edema due to increase in capillary permeability

DAILY SCREENING FORM

Ventilatory Management of ARDS. Alexei Ortiz Milan; MD, MSc

Thanks to Ben Taylor for his Grand Rounds talk which looks at the problems that may result from whacking on a bit of oxygen.

What is the next best step?

FOCUS CONFERENCE 2018

High-Frequency Percussive Ventilation Facilitates Weaning from Extracorporeal Membrane Oxygenation in Adults

Post-Resuscitation Care. Prof. Wilhelm Behringer Center of Emergency Medicine University of Jena

BASIC CRITICAL CARE OF THE PATIENT. Hannelisa Callisen PA C February 2017

ECMO Experience from ECMO-ICU, Karolinska

TITLE: Optimal Oxygen Saturation Range for Adults Suffering from Traumatic Brain Injury: A Review of Patient Benefit, Harms, and Guidelines

ECMO Primer A View to the Future

Identification and Treatment of the Patient with Sleep Related Hypoventilation

Adjuvants to Mechanical Ventilation for Acute Respiratory Failure

Inhaled nitric oxide: clinical evidence for use in adults

Images have been removed from the PowerPoint slides in this handout due to copyright restrictions.

Year in Review: Critical Care Medicine

Large observational study to UNderstand the Global impact of Severe Acute respiratory FailurE (LUNG-SAFE)

Best of Pulmonary Jennifer R. Hucks, MD University of South Carolina School of Medicine

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Section: Therapy Effective Date: July 15, 2015 Subsection: Original Policy Date: June 19, 2015 Subject:

Objective 2/9/2012. Blood Gas Analysis In The Univentricular Patient: The Need For A Different Perspective. VENOARTERIAL CO2 GRADIENT

SIMPLY Arterial Blood Gases Interpretation. Week 4 Dr William Dooley

Experience with Low Flow ECCO2R device on a CRRT platform : CO2 removal

Wet Lungs Dry lungs Impact on Outcome in ARDS. Charlie Phillips MD Division of PCCM OHSU 2009

Oxygenation Failure. Increase FiO2. Titrate end-expiratory pressure. Adjust duty cycle to increase MAP. Patient Positioning. Inhaled Vasodilators

Acute Respiratory Distress Syndrome (ARDS) An Update

E-CPR National Trends & Local Plans

E-CPR National Trends & Local Plans

ECMO CPR. Ravi R. Thiagarajan MBBS, MPH. Cardiac Intensive Care Unit

Prepared by : Bayan Kaddourah RN,MHM. GICU Clinical Instructor

ARF, Mechaical Ventilation and PFTs: ACOI Board Review 2018

Canadian Society of Internal Medicine Annual Meeting 2018 Banff, AB

Acid-Base Imbalance. Shu-Yi (Emily) Wang, PhD, RN, CNS Denver School of Nursing

Index. Note: Page numbers of article titles are in boldface type

ECMO/ECCO 2 R in Acute Respiratory Failure

5/15/2018. Background. Disclosure Statement

Application of Lung Protective Ventilation MUST Begin Immediately After Intubation

Transcription:

The Association Between Oxygenation Thresholds and Mortality During Extracorporeal Life Support Laveena Munshi, MD, MSc November 1, 2016 Critical Care Canada Forum Interdepartmental Division of Critical Care Medicine Mount Sinai Hospital/University Health Network University of Toronto Toronto, Canada

Disclosures: No Financial Disclosures Extracorporeal Life Support Organization Research Grant

Is It Possible to O.D. on O 2??

Hyperoxia Not Uncommon During ECLS?

Percent Mortality Objectives To evaluate the association between oxygen thresholds and hospital mortality in patients undergoing ECLS in 3 cohorts: 1.Venovenous ECMO for respiratory failure 2.Venoarterial ECMO for cardiogenic shock 3. ecpr for cardiac arrest 100 90 80 70 60 50 40 30 20 HYPOTHESIS 0 80 160 240 320 400 480 pao 2

Methods Retrospective Cohort Study Adult Patients Undergoing ECLS 2010-2015

Methods COHORT 1: VV ECMO RESP COHORT 2: VA ECMO CARDIAC COHORT 3: ecpr EXPOSURE OUTCOME STATISTICAL ANALYSIS Venous outflow/inflow or bicaval dual lumen Respiratory Indication (eg. ARDS) Venous outflow/arterial inflow or venous/arterial inflow Cardiac Indication (eg. post MI cardiogenic shock) Veno-arterial cannulation during cardiac arrest Oxygenation determined by ABG 24 hours after ECLS initiation Hypoxemia: PaO 2 <60mmHg Normoxia: PaO 2 60-100mmHg (ref) Moderate Hyperoxia:PaO 2 101-300 mmhg Extreme Hyperoxia: PaO 2 >301mmHg In-hospital Mortality Multivariable logistic regression analysis controlling for all clinically relevant confounders (Patient demographic, pre ECLS clinical data, post-ecls parameters)

Results

Cohort Creation Configuration, Indication and ABG Data n=7,337 VV ECMO VA ECMO VA ECMO VV ECMO RESP VA ECMO CARDIAC VA ECMO ecpr

Cohort Characteristics Mean (± Standard Deviation) Median (Interquartile Range) VV RESP VA CARDIAC ecpr Age 44 ± 16 52 ± 15 53 ± 16 Sex (% Male) 64% 67% 71% Weight 87 ± 28 82 ± 23 81 ± 22 Duration MV pre ECMO 55 hours (18-144) 15 hours (6-40) 2 hours (0-17) ABG pre ECMO 7.20/64/67/26 7.30/40/124/20 7.20/47/120/18 ph/pco 2 /O 2 /HCO 3 ECMO Mode VV 61% BCDL 38% VA 99% VVA 1% VA 99% VVA 1% ECMO Flow 4 ± 1 4 ± 1 3.5 ± 1 ABG post ECMO 7.23/41/94/26 7.40/36/180/22 7.40/34/195/23 ph/pco 2 /O 2 /HCO 3 Duration of ECMO (days) 8 (4-15) 5 (3-8) 4 (3-8) Discharged Alive 59% 41% 39%

Percent Distribution of Oxygenation 100 Hypoxemia <60 mmhg 90 80 70 60 52% 58% Normoxia 61-100 mmhg Mod Hyperoxia 101-300 mmhg Severe Extreme Hyperoxia Hyperoxia >300 >301 mmhg mmhg 50 46% 40 30 20 10 21% 25% 2% 8% 19% 15% 23% 8% 22% 0 VV ECMO RESP VA ECMO CARDIAC ecpr

Percent Crude Association Between O 2 and Mortality ---- VV ECMO RESP ---- VA ECMO CARDIO ---- ecpr pao 2

VV ECMO Respiratory Failure: Moderate Hyperoxia and Hypoxemia Associated with Increased Mortality Hypoxemia pao 2 <60 mm Hg (161 patients, 21%) Normoxia pao 2 60-100 mm Hg (394 patients, 52%) Moderate Hyperoxia pao 2 101-300 mm Hg (194 patients, 25%) Extreme Hyperoxia pao 2 >301 mm Hg (15 patients, 2%*) OR 95% CI 1.68 (1.09-2.57) 101-120 mmhg 121-140 mmhg 1 reference 141-160 mmhg 161-180 mmhg 1.66 181-200 (1.11-2.50) mmhg 201-220 mmhg 221-240 mmhg 0.75 (0.21-2.64) 241-260 mmhg *Older age, liver failure, higher peak inspiratory pressure at 24 hours, higher HCO 3, lower ph at 24 hours also statistically significantly associated with increased mortality

VA ECMO Cardiogenic Shock: No Association with Mortality Hypoxemia pao 2 <60 mm Hg (62 patients, 8%) Normoxia pao 2 60-100 mm Hg (145 patients, 19%) Moderate Hyperoxia pao 2 101-300 mm Hg (450 patients, 58%) Extreme Hyperoxia pao 2 >301 mm Hg (117 patients, 15%) OR 95% CI 1.67 (0.74-3.75) 1 reference 0.89 (0.59-1.34) 1.43 (0.80-1.00) *Older age, lower mean arterial pressure, post ECMO MV FiO2, lower ph & pco 2, statistically significantly associated with a higher mortality

VA ECMO ecpr: Moderate Hyperoxia Associated with Increased Mortality Hypoxemia pao 2 <60 mm Hg (96 patients, 23%) Normoxia pao 2 60-100 mm Hg (34 patients, 8%) Moderate Hyperoxia pao 2 101-300 mm Hg (191 patients, 46%) Extreme Hyperoxia pao 2 >301 mm Hg (91 patients, 22%) OR 95% CI 1.33 (0.48-3.69) 1 reference 1.77 (1.03-3.03) 1.92 (0.9-3.69) *post ECMO MV FiO2 & lower ph statistically significantly associated with a higher mortality

ECLS Types VV ECMO RESPIRATORY FAILURE VA ECMO CARDIOGENIC SHOCK VA ECMO ecpr Association w/ Mortality Moderate Hyperoxia Hypoxemia No Association Moderate Hyperoxia MECHANISM of HARM ASSOCIATED with HYPEROXIA: Direct Lung Toxicity Interstitial fibrosis, atelectasis, tracheobronchitis, ocular toxicity Systemic Hyperoxia Effect pro-inflammatory response, increased reactive O 2 species vasoconstriction leading to end organ dysfunction

Mechanism for Harm VV ECMO Oxygen free radicals exacerbated on ECMO Vasoconstriction induced by hyperoxia leading to MSOF Mechanisms to achieve higher arterial pao 2 may be harmful Higher ECMO flow Higher ventilation intensity Higher FiO2

No Harm Seen - VA ECMO Predominant mechanism of death may be due to underlying disease Death due to underlying disease may precede harm potentially attributable to hyperoxia VA ECMO deaths occurred earlier than VV ECMO

Death on VA ECMO Occurred Earlier than VV ECMO 90% 80% 70% 60% 50% 40% VA ECMO VV ECMO 30% 20% 10% 0% 24 HOURS 48 HOURS 72 HOURS 96 HOURS 120 HOURS 230 HOURS VA 90% deaths occurred by day 12 VV 90% 0f deaths occurred by day 30

Mechanism for Harm ecpr Consistent with reports of increased harm in literature with for anoxic brain injury population Neurologic injury and brain edema following cardiac arrest particularly susceptible to O 2 free radicals and vasocontriction

Limitations: Exploratory analysis Adequate capture of exposure? (24 hour time point ABG) Bias towards the null Clustering at hospital level Would impact standard errors but not point estimates Selection Bias Sufficient Control for Confounding

O 2 : Too Much of a Good Thing?? Recent growing body of literature over the past 6 years suggesting harm associated with hyperoxia Recent growing body of literature surrounding lower O 2 thresholds at which potential harm may be seen

RCT, 434 Patients, MSICU MSICU, anticipated admission >72 hours CONSERVATIVE pao 2 70-100 mmhg Potential Overestimation of Treatment Effect CONVENTIONAL paostopped 2 up 150 Early mmhg Saturation 94-98% Saturation Baseline 97-100% imbalances Exclude ARDS with PaO2/FiO2 Small <150mmHg number of Outcomes Chronically hypercapnic COPD Underpowered

Conclusions and Future Directions Moderate hyperoxia (pao 2 101-300 mmhg) associated with increased mortality in select cohorts of ECLS (VV ECMO Respiratory Failure and VA ECMO for ecpr) Possible mechanisms: vasoconstriction and oxygen free radicals or harm associated with increased ECLS or MV intensity to achieve higher O 2 Lack of association between hyperoxia and mortality in VA ECMO may be attributable to death due to underlying disease process Future research needed to further confirm results, explore thresholds, understand duration and dose-response as well as mechanisms for harm

A word of caution for the visitors to Toronto regarding your Tuesday night plans..

Oxygen bars are places people can go to inhale high purity Oxygen for recreation and relaxation. It is a fun and profitable business that succeeds in many different settings. The first "Oxygen Bar" in North America was the "Oxygen Spa Bar" opened by <name omitted> in Toronto Canada in 1995. $5.00/3 minutes

Acknowledgements Dr. Eddy Fan Dr. Alex Kiss Dr. Niall Ferguson Dr. Shaf Keshavgee Dr. Marcelo Cypel ELSO Research Grant

Interaction (exploratory) VV ECMO RESP VA ECMO CARDIAC MORTALITY Resp Acidosis <7.35, >45 Resp Alkalosis >7.45, <35 Full VV Resp Cohort MORTALITY Resp Acidosis <7.35, >45 Resp Alkalosis >7.45, <35 Full VA Cardiac Cohort Hypoxemia 48% (56) 39% (77) 36% Hypoxemia <60 92% 61% 64% Normoxia 43% (86) 41% (34) 39% Normoxia 61-100 76% 53% 57% Hyperoxia 27% (11) 42% (52) 45% Hyperoxia 101-300 56% 52% 56% Hyperoxia 100% (3) 33% (6) 46% Hyperoxia >301 79% 60% 67%

Appendix Table 1: Variables Incorporated Into Each Model (*determined by clinical relevance) VV ECMO RESP VA ECMO CARDIAC ecpr Sex Race Age Weight Year Sex Race Age Weight Year Sex Race Age Weight Year Pre ECMO ABG data Pre ECMO Duration of MV Pre ECMO Vent (FiO2, PIP, PEEP) Pre ECMO MAP Pre ECMO Vasopressors Pre ECMO CVVHD Pre ECMO Narcotics Pre ECMO NMBA Pre ECMO ino Pre ECMO Steroids Acute Comorbid Conditions Pre ECMO (cardiac, AKI, acute liver failure) Post ECMO flow Post ECMO vent parameters Post ECMO ABG data Pre ECMO ABG data Pre ECMO Duration of MV Pre ECMO Vent (FiO2, PIP, PEEP) Pre ECMO MAP Pre ECMO Vasopressors Pre ECMO CVVHD Pre ECMO Narcotics Pre ECMO CPB, ino Pre ECMO paced Pre ECMO Steroids Acute Comorbid Conditions Pre ECMO (resp failure, AKI, acute liver failure) Post ECMO flow Post ECMO vent parameters Post ECMO ABG data Post ECMO flow Post ECMO vent parameters Post ECMO ABG data MAP *did not include pre-ecmo ABG and MV data as the majority are not intubated pre-arrest

VV ECMO pao 2 Detailed Overview Moderate Hyperoxia ECMO pao2 mmhg OR 95% CI 100-120 1.97 (0.84-4.65) 120-140 1.17 (0.29 4.66) 141-160 0.717 (0.10-5.34) 161-180 3.56 (0.26-49.38) 181-200 3.16 (0.14-71.34) 201-220 3.99 (0.10-153.99) 221-240 3.62 (0.04-361.24) 241-260 1.49 (0.01-201.86) 280-300 0.96 (0.002-415.50)

(VV) 90% of deaths occurred by day 30 Timing of Death Across those who Died on ECMO 90.00% 80.00% 70.00% 60.00% 50.00% 40.00% VA ECMO VV ECMO 30.00% 20.00% 10.00% 0.00% 24 HOURS 48 HOURS 72 HOURS 96 HOURS 120 HOURS 230 HOURS (VA) 90% of deaths occurred by day 12

100 90 80 70 60 50 40 VV ECMO VA ECMO ecpr 30 20 10 0 0 2 4 6 8 10 12 Days

Percent Distribution of Oxygenation 100 90 80 70 VV ECMO RESP VA ECMO CARDIAC ecpr 60 50 40 30 20 10 0 Hypoxia Normoxia Moderate Hyperoxia Severe Hyperoxia <60mmHg 61-100mmHg 101-300mmHg >300mmHg